Evidence map›Paper›PMID 34743024›Full record

ArticleToxicology2022

Predicting the effects of per- and polyfluoroalkyl substance mixtures on peroxisome proliferator-activated receptor alpha activity in vitro.

Greylin Nielsen, Wendy J Heiger-Bernays, Jennifer J Schlezinger, Thomas F Webster

Open access · greenAbstract readComparative Study
In one paragraph

Article in Toxicology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Greylin NielsenBoston University School of Public Health, Department of Environmental Health, Boston, MA, 02118, USA. Electronic address: nielseng@bu.edu.
Wendy J Heiger-BernaysBoston University School of Public Health, Department of Environmental Health, Boston, MA, 02118, USA.
Jennifer J SchlezingerBoston University School of Public Health, Department of Environmental Health, Boston, MA, 02118, USA. Electronic address: jschlezi@bu.edu.
Thomas F WebsterBoston University School of Public Health, Department of Environmental Health, Boston, MA, 02118, USA. Electronic address: twebster@bu.edu.
Boston University · US

Funding

Environmental Epidemiology in Community SettingsT32ES014562 · NIEHS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Birgit Gunhild Claus Henn · 2006 to 2026
$7.7M
Novel Analytical and Experimental Approaches for Predicting the Biological Effects of MixturesR01ES027813 · NIEHS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI WEBSTER, THOMAS F · 2017 to 2021
$2.2M
NIEHS NIH HHS R01 ES027813NIEHS NIH HHS T32 ES014562
6 · The paper itself

Abstract

Human exposure to per- and polyfluoroalkyl substances (PFAS) is ubiquitous, with mixtures of PFAS detected in drinking water, food, household dust, and other exposure sources. Animal toxicity studies and human epidemiology indicate that PFAS may act through shared mechanisms including activation of peroxisome proliferator activated receptor α (PPARα). However, the effect of PFAS mixtures on human relevant molecular initiating events remains an important data gap in the PFAS literature. Here, we tested the ability of modeling approaches to predict the effect of diverse PPARα ligands on receptor activity using Cos7 cells transiently transfected with a full length human PPARα (hPPARα) expression construct and a peroxisome proliferator response element-driven luciferase reporter. Cells were treated for 24 h with two full hPPARα agonists (pemafibrate and GW7647), a full and a partial hPPARα agonist (pemafibrate and mono(2-ethylhexyl) phthalate), or a full hPPARα agonist and a competitive antagonist (pemafibrate and GW6471). Receptor activity was modeled with three additive approaches: effect summation, relative potency factors (RPF), and generalized concentration addition (GCA). While RPF and GCA accurately predicted activity for mixtures of full hPPARα agonists, only GCA predicted activity for full and partial hPPARα agonists and a full agonist and antagonist. We then generated concentration response curves for seven PFAS, which were well-fit with three-parameter Hill functions. The four perfluorinated carboxylic acids (PFCA) tended to act as full hPPARα agonists while the three perfluorinated sulfonic acids (PFSA) tended to act as partial agonists that varied in efficacy between 28-67 % of the full agonist, positive control level. GCA and RPF performed equally well at predicting the effects of mixtures with three PFCAs, but only GCA predicted experimental activity with mixtures of PFSAs and a mixture of PFCAs and PFSAs at ratios found in the general population. We conclude that of the three approaches, GCA most accurately models the effect of PFAS mixtures on hPPARα activity in vitro. Understanding the differences in efficacy with which PFAS activate hPPARα is essential for accurately predicting the effects of PFAS mixtures. As PFAS can activate multiple nuclear receptors, future analyses should examine mixtures effects in intact cells where multiple molecular initiating events contribute to proximate effects and functional changes.

Indexed as

Models, MolecularAnimalsCarboxylic AcidsChlorocebus aethiopsCOS CellsDose-Response Relationship, DrugDrug Partial AgonismHydrocarbons, FluorinatedMolecular StructurePPAR alphaSignal TransductionStructure-Activity RelationshipSulfonic AcidsCarboxylic AcidsHydrocarbons, FluorinatedPPAR alphaPPARA protein, humanSulfonic AcidsMixturesNuclear receptor signalingPartial agonistPer- and polyfluoroalkyl substancesPPARαPredictive biological modeling

Identifiers

PMID34743024
PMCPMC8692422
OpenAlexW3213863989

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.